Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiaowei, Shi, Qiyun, Xuhong, Juncheng, Zhang, Yi, Jiang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546716/
https://www.ncbi.nlm.nih.gov/pubmed/37789330
http://dx.doi.org/10.1186/s13058-023-01694-5
_version_ 1785114917705089024
author Qi, Xiaowei
Shi, Qiyun
Xuhong, Juncheng
Zhang, Yi
Jiang, Jun
author_facet Qi, Xiaowei
Shi, Qiyun
Xuhong, Juncheng
Zhang, Yi
Jiang, Jun
author_sort Qi, Xiaowei
collection PubMed
description Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved prognosis for patients. Compared with widely used monoclonal antibodies, small-molecule TKIs have unique advantages including oral administration and favorable penetration of blood–brain barrier for brain metastatic BC, and reduced cardiotoxicity. Pyrotinib is an irreversible TKI of the pan-ErbB receptor, and has recently been shown to be clinically effective for the treatment of HER2-positive BC in metastatic and neoadjuvant settings. This review highlights the development on the application of pyrotinib-based therapeutic approaches in the clinical settings of HER2-positive BC.
format Online
Article
Text
id pubmed-10546716
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105467162023-10-04 Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now Qi, Xiaowei Shi, Qiyun Xuhong, Juncheng Zhang, Yi Jiang, Jun Breast Cancer Res Review Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved prognosis for patients. Compared with widely used monoclonal antibodies, small-molecule TKIs have unique advantages including oral administration and favorable penetration of blood–brain barrier for brain metastatic BC, and reduced cardiotoxicity. Pyrotinib is an irreversible TKI of the pan-ErbB receptor, and has recently been shown to be clinically effective for the treatment of HER2-positive BC in metastatic and neoadjuvant settings. This review highlights the development on the application of pyrotinib-based therapeutic approaches in the clinical settings of HER2-positive BC. BioMed Central 2023-10-03 2023 /pmc/articles/PMC10546716/ /pubmed/37789330 http://dx.doi.org/10.1186/s13058-023-01694-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Qi, Xiaowei
Shi, Qiyun
Xuhong, Juncheng
Zhang, Yi
Jiang, Jun
Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
title Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
title_full Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
title_fullStr Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
title_full_unstemmed Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
title_short Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
title_sort pyrotinib-based therapeutic approaches for her2-positive breast cancer: the time is now
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546716/
https://www.ncbi.nlm.nih.gov/pubmed/37789330
http://dx.doi.org/10.1186/s13058-023-01694-5
work_keys_str_mv AT qixiaowei pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow
AT shiqiyun pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow
AT xuhongjuncheng pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow
AT zhangyi pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow
AT jiangjun pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow

Ejemplares similares